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Summary
Background.  —  Vascular  complications  (VCs)  after  transcatheter  aortic  valve  implantation  (TAVI)
are frequent  and  their  management  is  challenging.
Aim.  —  To  report  the  incidence,  predictors  and  management  of  VCs  following  percutaneous
transfemoral  TAVI  (TF-TAVI)  at  a  single  centre.
Methods.  —  We  analyzed  102  consecutive  patients  who  underwent  percutaneous  TF-TAVI
between August  2008  and  December  2013.  All  endpoints  were  evaluated  at  30  days  and  6  monthsCovered  stent according to  Valve  Academic  Research  Consortium-2  criteria.  VC  percutaneous  treatment  suc-
cess was  deﬁned  as  residual  stenosis  <  30%,  absence  of  blood  extravasation  and  absence  of
surgical or  repeat  endovascular  intervention  at  30  days.
Results.  —  Twenty-two  patients  (22%)  experienced  VCs,  including  ﬁve  patients  (5%)  with  major
VCs. Mortality  at  30  days  was  signiﬁcantly  higher  in  patients  with  major  VCs  than  in  patients
Abbreviations: AS, Aortic stenosis; CI, Conﬁdence interval; MSCT, Multislice computed tomography; TAVI, Transcatheter aortic valve
implantation; TF, Transfemoral; VARC, Valve Academic Research Consortium; VC, Vascular complication.
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without  major  VCs  (60%  vs  3%;  P  =  0.001).  Patients  with  VCs  had  more  life-threatening  or  major
bleeding (23%  vs  5%;  P  =  0.02),  but  no  difference  in  terms  of  need  for  blood  transfusion  was
observed.  Endovascular  treatment  was  used  in  13  of  22  patients  with  VCs  (59%)  and  was  suc-
cessful in  11  of  these  13  patients  (85%).  Primary  surgical  repair  was  necessary  in  only  1/22  (5%)
patients,  for  a  common  femoral  artery  pseudoaneurysm  2  weeks  after  the  TAVI  procedure.
Conclusions.  —  VCs  following  TF-TAVI  are  frequent.  Major  but  not  minor  VCs  are  associated  with
increased  mortality.  Percutaneous  management  of  VCs  is  feasible  and  safe,  and  surgery  is  rarely
needed.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  Les  complications  vasculaires  (CV)  liées  au  remplacement  valvulaire  aortique  per-
cutané (RVAP)  sont  fréquentes  et  leur  prise  en  charge  reste  complexe.
Objectif.  —  Rapporter  l’incidence,  les  facteurs  prédictifs  et  la  prise  en  charge  des  CV  liées  au
RVAP transfémoral  (TF)  dans  notre  institution.
Méthodes.  —  Analyse  basée  sur  102  patients  consécutifs  ayant  bénéﬁcié  d’un  RVAP  TF  entre
août 2008  et  décembre  2013.  Tous  les  critères  d’évaluation  étaient  établis  conformément  au
Valve Academic  Research  Consortium-2  et  évalués  à  30  jours  et  6  mois.  Le  succès  du  traitement
était déﬁni  par  l’absence  d’une  sténose  résiduelle  >  30  %,  l’absence  d’un  saignement  résiduel,
et l’absence  d’une  reprise  endovasculaire  ou  chirurgicale  à  30  jours.
Résultats.  —  Vingt-deux  patients  (22  %)  ont  développé  des  CV,  dont  5  %  de  CV  majeures.  La  mor-
talité à  30  jours  était  signiﬁcativement  supérieure  chez  les  patients  avec  des  CV  majeures  que
chez les  patients  sans  CV  majeure  (60  %  vs  3  %;  p  =  0,001).  Les  taux  de  saignements  critiques
ou majeurs  étaient  plus  élevés  parmi  les  patients  avec  une  CV  (23  %  vs  5  %;  p  =  0,02),  sans
qu’aucune  différence  en  termes  de  besoin  de  transfusion  sanguine  n’ait  été  mise  en  évidence.
Cinquante-neuf  virgule  un  pour  cent  des  patients  avec  une  CV  (13/22)  ont  bénéﬁcié  d’un  traite-
ment endovasculaire,  avec  un  taux  de  succès  de  85  %  (11/13).  Une  réparation  chirurgicale  en
première intention  n’a  été  nécessaire  que  chez  1/22  patients  (5  %)  pour  la  prise  en  charge  d’un
pseudo-anévrisme  de  l’artère  fémorale  commune  2  semaines  après  le  RVAP.
Conclusions.  — Les  CV  liées  au  RVAP  sont  fréquentes.  Les  CV  majeures,  contrairement  aux
mineures,  sont  associées  à  une  mortalité  augmentée.  Un  traitement  endovasculaire  des  CV
est dans  la  majorité  des  cas  envisageable.
© 2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
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self-expanding  CoreValve® device  (Medtronic  Inc.,  Min-ackground
s  the  population  is  aging,  physicians  are  increasingly  con-
ronted  by  patients  with  multiple  morbidities  and  very
lderly  patients  with  symptomatic  aortic  valve  stenosis  (AS)
ho  are  not  eligible  or  are  at  high  risk  for  surgical  aor-
ic  valve  replacement.  According  to  data  from  randomized
rials,  transcatheter  aortic  valve  implantation  (TAVI)  has
ecome  the  new  standard  of  care  for  inoperable  patients
nd  is  a  valid  (if  not  superior)  option  for  high-risk  patients
1—3].  During  the  last  decade,  the  reduction  in  diameter  of
he  delivery  systems,  in  conjunction  with  better  preopera-
ive  vascular  screening  and  increasing  operator  experience
ave  led  to  a  reduction  in  vascular  complications  (VCs).
owever,  VCs  remain  the  most  frequent  adverse  events
ssociated  with  transfemoral  TAVI  (TF-TAVI)  procedures  [4].
n  the  early  days  of  TAVI  use,  such  complications  were
ainly  managed  surgically  under  general  anaesthesia.  With
rowing  TAVI  experience,  endovascular  treatment  of  VC  has
een  increasingly  adopted.  In  this  report,  we  describe  a
n
s
3ingle-centre  experience  of  the  incidence,  predictors,  man-
gement  and  outcomes  of  VCs  at  30  days  and  6  months  in
atients  undergoing  percutaneous  TF-TAVI.
ethods
atient population
etween  August  2008  (the  beginning  of  the  TAVI  programme
t  our  institution)  and  December  2013,  102  consecutive
atients  underwent  purely  percutaneous  TF-TAVI  for  symp-
omatic,  severe  AS,  severe  aortic  regurgitation  (one  patient)
r  degenerated  bioprosthesis  (one  patient).  All  procedures
ere  performed  by  two  operators  (S.  N.,  M.  R.)  using  theeapolis,  MN,  USA),  which  requires  an  18-French  introducer
heath  for  the  four  different  available  sizes  (23,  26,  29  and
1).  TF-TAVI  accounted  for  92%  of  the  TAVI  volume  during
a
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this  period  of  time.  As  four  patients  underwent  planned,
surgical,  femoral  cut-down  because  of  signiﬁcant  vascu-
lar  calciﬁcation,  purely  percutaneous  TF-TAVI  corresponded
to  89%  of  our  TAVI  experience.  Patients  were  selected  for
TF-TAVI  by  a  local  heart  team,  involving  cardiac  surgeons,
interventional  cardiologists,  cardiovascular  anaesthesiolo-
gists  and  intensive  care  specialists.  Risk  scores,  such  as  the
logistic  EuroSCORE  and  the  Society  of  Thoracic  Surgeons’
(STS)  score,  were  calculated  as  part  of  the  evaluation.  Ini-
tially,  frailty  was  assessed  using  the  ‘‘eye  ball  test’’,  but
from  2012  onwards  a  standardized  assessment  was  per-
formed  using  the  gait-speed  test,  grip  strength  assessment,
serum  albumin  concentration  and  evaluation  of  recent
weight  loss,  falls  and  mobility  impairment  (due  to  severe
musculoskeletal  or  neurological  disorders).  All  patients  gave
written  informed  consent  to  the  TAVI  procedure  and  the  use
of  related  data  for  research  and  publication.
Preoperative evaluation
All  patients  underwent  a  complete  assessment  of  medical
history,  a  physical  examination,  transthoracic  echocardi-
ography  and  baseline  biological  screening  to  assess  blood
count,  coagulation,  electrolyte  and  brain  natriuretic  pep-
tide  concentrations,  as  well  as  kidney  and  liver  function.
Aortic  annulus  and  root  dimensions  were  systematically
assessed  using  multislice  computed  tomography  (MSCT)
or  three-dimensional  transoesophageal  echocardiography
versus  magnetic  resonance  imaging  for  patients  with  a
creatinine  clearance  <  40  mol/L.  An  abdominal  aortogra-
phy  (including  iliofemoral  vessels)  and  selective  femoral
angiographies  were  routinely  performed  at  the  time  of
the  coronary  angiogram  and  right  heart  catheterization,  to
assess  the  iliofemoral  axis.  The  minimal  vessel  diameter  (at
least  6  mm),  tortuosity  and  calciﬁcation  were  speciﬁcally
evaluated.  An  additional  vascular  assessment  with  MSCT
(extension  of  the  cardiac  MSCT  down  to  the  femoral  bifur-
cation)  was  performed  for  the  ﬁrst  time  in  December  2010
and  routinely  since  January  2012.
Procedure
At  the  beginning  of  the  TAVI  intervention,  the  femoral
angiography  performed  during  screening  was  routinely
reviewed  to  visualize  the  relation  between  the  femoral
head,  the  inferior  epigastric  artery  and  the  femoral
bifurcation.  Once  vascular  access  was  obtained,  femoral
angiography  was  performed  to  document  correct  position-
ing.  The  self-expandable  Medtronic  CoreValve  System  was
introduced  through  an  18-French  introducer  sheath  (in
the  majority  of  cases  Cook  Medical,  Bloomington,  Indi-
ana,  USA)  or  a  19-French  balloon  expandable  SoloPath®
sheath  (Onset  Medical,  a  subdivision  of  Terumo  Medical
Corporation,  Irvine,  CA,  USA).  The  cutoff  limit  to  use  the
introducer  sheath  was  a  6-mm  iliofemoral  diameter.  The
procedure  steps  have  been  described  in  detail  [5].  Preclo-
sure  was  performed  in  all  patients  using  the  Prostar® XL
10  suture-based  vascular  closure  device  (Abbott  Vascular,
Reedwood  City,  CA,  USA).  At  the  end  of  the  procedure,
ﬁnal  crossover  angiography  of  the  main  vascular  access  was
systematically  performed  from  the  contralateral  femoral
puncture  site  to  verify  arteriotomy  closure  success  as  well
a
a
m
s493
s  iliofemoral  vessel  integrity.  The  antithrombotic  regimen
uring  the  procedure  consisted  of  aspirin  and  a standard
ose  of  unfractionated  heparin  (5000  U),  with  activated
lotting  time  checks  when  the  procedure  was  longer  than
xpected.  Initially  a  loading  dose  of  clopidogrel  was  admin-
stered  the  night  before  the  procedure,  but  since  2012
lopidogrel  has  been  given  immediately  after  the  proce-
ure  and  for  3  months  —– when  no  vitamin  K antagonist  is
equired  —– followed  by  aspirin  or  clopidogrel  monotherapy
ndeﬁnitely.
anagement of vascular complications
issections  detected  during  the  ﬁnal  angiography  were
reated  by  balloon  angioplasty  and,  in  cases  of  a  suboptimal
ngioplasty  result,  self-expanding  uncovered  nitinol  stents
ere  implanted  (S.M.A.R.T.® [Cordis  Corporation,  Hialeah,
L  USA]  and  Misago® [Terumo  Corporation,  Tokyo,  Japan]).
ncomplete  arteriotomy  closure  or  iliofemoral  leakages  were
anaged  ﬁrst,  depending  on  the  severity  of  the  ﬁndings,
ith  prolonged  manual  compression,  balloon  occlusion  of
he  iliac  axis  using  the  contralateral  access,  reversal  of
nfractionated  heparin  with  protamine  administration  or
 combination  of  these  manoeuvres.  Covered  stents  were
mplanted  in  cases  of  persistent  vascular  leakage  (other
han  trace)  despite  prolonged  manual  compression.  Femoral
seudoaneurysm  resistant  to  manual  or  echocardiography
uided  compression  were  treated,  depending  on  their  loca-
ion,  with  thrombin  injection,  covered  stent  implantation  or
urgery.  The  covered  stents  used  were  either  self-expanding
lgiloy  stents  covered  with  a layer  of  polyethylene  tereph-
halate  (WALLGRAFT®;  Boston  Scientiﬁc,  Natick,  MA,  USA)
r  self-expanding  nitinol  stents  covered  with  polytetraﬂu-
roethylene  (Fluency®;  Bard  Peripheral  Vascular,  Phoenix,
Z,  USA).  VC  percutaneous  treatment  success  was  deﬁned
s  residual  stenosis  <  30%,  absence  of  blood  extravasation  at
nal  angiography  and  absence  of  surgical  or  repeat  endovas-
ular  intervention  at  30  days.  Endovascular  treatment  of  VCs
as  performed  by  two  interventional  cardiologists  (M.  R.,
.  N.),  one  of  whom  (M.  R.)  is  trained  in  peripheral  vascular
reatment  and  performs  more  than  100  peripheral  vascular
nterventions  per  year.
tudy endpoints
ll  endpoints  were  evaluated  at  30  days  and  6  months
ollowing  TAVI  according  to  the  Valve  Academic  Research
onsortium-2  (VARC-2)  criteria  [6]. VCs  were  stratiﬁed
s  major  whenever  a  vascular  injury  led  to  death,  life-
hreatening  or  major  bleeding,  visceral  ischaemia  or
eurological  impairment.  Minor  VCs  were  deﬁned  as  vascu-
ar  injury  not  leading  to  adverse  events  deﬁning  a  major
C.  A  bleeding  event  was  considered  as  life-threatening
f  it  occurred  in  vital  organs  (i.e.  intracranial,  intraspinal,
ntraocular  or  pericardial),  provoked  haemorrhagic  shock  or
eeded  at  least  4  units  of  packed  red  blood  cells,  or  when-
ver  a  >  5 g/dL  drop  in  haemoglobin  was  reported.  Bleeding
as  considered  as  major  when  overt  bleeding  was  either
ssociated  with  a  >  3  g/dL  drop  in  haemoglobin  or  required
t  least  2  units  of  packed  red  blood  cells.  The  study  pri-
ary  outcome  measure  was  the  occurrence  of  any  VC.  The
econdary  outcome  measure  included  30-day  incidence  of
4 N.  Perrin  et  al.
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Table  1  Baseline  characteristics  for  the  total  cohort
(n  =  102).
Women  64  (62.8)
Age  (years)  85.0  [76.0—94.0]
BMI  (kg/m2) 25.6  ±  5.3
Dyslipidaemia  56  (54.9)
Diabetes  mellitus  30  (29.4)
Smoking
Never  or  past  96  (94.1)
Current  6  (5.9)
Hypertension  75  (73.5)
Chronic  obstructive  pulmonary  disease  25  (24.5)
Peripheral  vascular  disease 20  (19.6)
Coronary  artery  disease  54  (52.9)
Previous  myocardial  infarction  20  (19.6)
Previous  CABG  13  (12.8)
Previous  PCI 42  (41.2)
Previous  cerebral  stroke 10  (9.8)
NYHA
0—2 23  (22.6)
3—4 79  (77.5)
GFR  (mL/min/1.73  m2) 50.0  [36.0—64.0]
Aortic  valve  area  (cm2) 0.68  ±  0.19
Aortic  peak  velocity 4.1  ±  0.7
Mean  aortic  gradient  (mmHg) 39.2  [22.4—56.0]
Left  ventricular  ejection  fraction  (%) 60  [47—73]
Logistic  EuroSCORE  (%) 18.1  [3.6—32.5]
STS  score  (%) 6.8  [2.1—11.5]
Data are expressed as number (%), median [interquartile range]
or mean ± standard deviation. BMI: body mass index; CABG:
coronary artery bypass graft; GFR: glomerular ﬁltration rate;
NYHA: New York Heart Association; PCI: percutaneous coronary
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ife-threatening  or  major  bleeding  and  30-day  as  well  as
-month  overall  and  cardiovascular  mortality.  An  expert
nterventional  cardiologist  performed  endpoint  adjudica-
ion.
ata collection
aseline  characteristics,  periprocedural  data  and  adverse
vents  during  the  index  hospital  stay,  and  at  30-day  and  6-
onth  clinical  follow-up  were  routinely  collected  as  part  of
ur  local  prospective  registry  approved  by  the  local  ethics
ommittee.  Procedure  angiographic  images  and  iliofemoral
SCT,  when  available,  were  analyzed  retrospectively  with
espect  to  iliofemoral  calciﬁcation,  atherosclerosis,  tortu-
sity  and  femoral  bifurcation  location.  A  femoral  artery
alciﬁcation  score  using  angiographic  images  just  before
ontrast  injection  was  adapted  from  the  coronary  artery
alciﬁcation  score  ﬁrst  described  by  Yamanaka  et  al.,  allow-
ng  for  a  semiquantitative  and  reproducible  assessment  of
liofemoral  vessel  calciﬁcation  [7].  Brieﬂy,  it  is  deﬁned  as
ollows:  0  =  no  calciﬁcation;  1  =  spotty  wall  calciﬁcation;
 =  unilateral  linear  calciﬁcation;  3  =  unilateral  linear  calci-
cation  with  spotty  wall  calciﬁcation  on  the  opposite  wall;
 =  bilateral  linear  calciﬁcation.  The  distance  between  the
uncture  site  and  the  inferior  epigastric  artery  as  well  as
he  femoral  bifurcation  was  systematically  measured  on  the
nal  ﬂuoroscopic  acquisition  using  the  most  contrast-ﬁlled
mage.  We  used  the  slight  Prostar-induced  vessel  stenosis  to
dentify  exact  location  of  the  puncture  site.  Finally,  to  assess
he  effect  of  the  learning  curve  on  incidence  of  VCs,  the
ohort  was  arbitrarily  separated  in  two  halves  (51  patients
n  each  group)  before  executing  the  statistical  analysis.
tatistical analysis
he  distribution  of  continuous  variables  was  assessed  using
he  Shapiro—Wilks  test.  Normally  distributed  variables  are
resented  as  means  ±  standard  deviations  and  non-normally
istributed  variables  as  medians  [interquartile  ranges].
ifferences  were  compared  using  Student’s  t-test  or  the
ilcoxon  rank-sum  test,  as  appropriate.  Categorical  data
re  expressed  as  numbers  and  frequencies  (%),  and  were
ompared  with  Fisher’s  exact  test  or  Pearson’s  2 test.
ultivariable  logistic  regression  was  used  to  identify  inde-
endent  predictors  of  VCs.  Variables  with  a  P-value  <  0.1
ere  entered  in  the  regression  model,  and  variables  known
o  be  associated  with  an  increased  risk  of  VCs  (sex  and  vas-
ular  calciﬁcation)  were  included  a  priori  into  the  analysis.
ll  statistical  analyses  were  performed  using  Stata  SE  (Stata
orp,  College  Station,  TX,  USA;  2011).
esults
atient population
he  baseline  characteristics  and  echocardiographic  varia-
les  of  the  102  consecutive  patients  with  percutaneous
F-TAVI  interventions  performed  at  our  centre  are  presented
n  Table  1.  Table  2  compares  the  baseline  characteristics  of
he  patients  with  and  without  VCs;  no  signiﬁcant  differences
etween  the  two  groups  in  terms  of  risk  factors,  medical
o
o
b
mintervention; STS: Society of Thoracic Surgeons.
istory  or  preprocedure  echocardiographic  characteristics
ere  found.
ascular complications
wenty-two  patients  (22%)  experienced  VCs.  Major  VCs
ccounted  for  23%  of  the  VCs  and  involved  ﬁve  patients  (5%
f  the  cohort),  whereas  minor  VCs  were  found  in  17  patients
77%  of  the  VCs;  17%  of  the  cohort).
Among  the  major  VCs,  two  did  not  involve  the  iliofemoral
xis.  The  ﬁrst  was  a  rupture  at  the  level  of  the  aortoven-
ricular  junction,  related  to  balloon  aortic  valvuloplasty,
hich  led  to  procedural  death.  No  conversion  to  surgery  was
ttempted,  according  to  the  patient’s  will.  The  second  was
 mesenteric  ischaemia,  clinically  suspected  24  hours  post-
rocedure,  most  probably  due  to  distal  embolisms  caused
y  CoreValve  embolization  and  recapture  through  the  18-
rench  sheath.  After  multidisciplinary  discussion,  no  surgery
as  attempted  —– given  the  patient’s  comorbidities  —– and
he  died  at  day  7.
The  three  remaining  major  VCs  were  located  at  the  level
f  the  iliofemoral  axis  or  inferior  limb.  One  of  these  patients,
n  aspirin  100  mg  and  intravenous  heparin  therapy  while
eing  switched  to  vitamin  K  antagonist  treatment  for  a
echanical  mitral  valve  prosthesis,  presented  with  a  large
TAVI  and  vascular  complications  495
Table  2  Differences  in  baseline  characteristics  between  patients  with  and  without  vascular  complications.
Overall  Patients  with  VCs  Patients  without  VCs  P
(n  =  102)  (n  =  22)  (n  =  80)
Sex  0.92
Female  64  (62.8)  14  (63.6)  50  (62.5)
Male  38  (37.3)  8  (36.4)  30  (37.5)
Age  (years)  85.0  [76.0—94.0]  85.0  [77.0—93.0]  85.5  [76.5—94.5]  0.59
BMI  (kg/m2)  25.6  ±  5.3  26.0  ±  5.1  25.4  ±  5.3  0.68
Dyslipidaemia  56  (54.9)  10  (45.5)  46  (57.5)  0.32
Diabetes  mellitus  30  (29.4)  6  (27.3)  24  (30.0)  0.90
Smoking  0.34
Never  or  past 96  (94.1) 22  (100.0) 74  (92.5)
Current  6  (5.9)  0  6  (7.5)
Hypertension  75  (73.5)  14  (63.6)  61  (76.3)  0.24
COPD  25  (24.5)  5  (22.7)  20  (25.0)  0.83
Peripheral  vascular  disease  20  (19.6)  5  (22.7)  15  (18.8)  0.76
Coronary  artery  disease  54  (52.9)  9  (40.9)  45  (56.3)  0.20
Previous  MI 20  (19.6)  2  (9.1)  18  (22.5)  0.22
Previous  CABG  13  (12.8)  4  (18.2)  9  (11.3)  0.47
Previous  PCI 42  (41.2)  7  (31.8)  35  (43.8)  0.31
Previous  cerebral  stroke 10  (9.8) 4 (18.2)  6  (7.5)  0.22
NYHA  0.58
0—2 23  (22.6) 4  (18.2)  19  (23.8)
3—4 79  (77.5) 18  (81.8) 61  (76.3)
GFR  (mL/min/1.73  m2) 50.0 [36.0—64.0] 49.8  [28.6—71.0]  50.5  [37.0—63.0]  0.60
Aortic  valve  area  (cm2) 0.68  ±  0.19 0.69  ±  0.17 0.68  ±  0.20  0.42
Aortic  peak  velocity  (m/s) 4.1  ±  0.7 3.9  ±  0.1 4.1  ±  0.1 0.20
Mean  aortic  gradient  (mmHg) 39.2  [22.4—56.0] 35.5  [20.2—50.8] 40.0  [21.7—58.3]  0.26
LVEF  (%) 60  [47—73] 60  [57—63] 60  [45—75] 0.29
Logistic  EuroSCORE  (%)  18.1  [3.6—32.5]  18.3  [7.3—29.2]  18.1  [3.5—32.1]  0.79
STS  score  (%)  6.8  [2.1—11.5]  8.4  [3.7—13.1]  6.5  [2.2—10.9]  0.26
Data are expressed as number (%), median [interquartile range] or mean ± standard deviation. BMI: body mass index; CABG: coronary
artery bypass graft; COPD: chronic obstructive pulmonary disease; GFR: glomerular ﬁltration rate; LVEF: left ventricular ejection
fraction; MI: myocardial infarction; NYHA: New York Heart Association; PCI: percutaneous coronary intervention; STS: Society of
Thoracic Surgeons; VC: vascular complication.
Table  3  Classiﬁcation  of  vascular  complications  for
the  total  cohort  (n  =  102),  according  to  Valve  Academic
Research  Consortium-2.
Variable  n (%)
Minor  vascular  complications  17  (16.7)
Vascular  dissection  10  (9.8)
Occlusive  2  (2.0)
Non-occlusive  8  (7.8)
Pseudoaneurysm  5  (4.9)
Haematoma  2  (2.0)
Major  vascular  complications  5  (4.9)
Vascular  dissection  1  (1.0)
Occlusive  1  (1.0)
Non-occlusive  0
Haematoma  with  transient  crural  nerve
paresia
1  (1.0)inguinal  haematoma  causing  transient  crural  nerve  paresis,
but  without  obvious  VC.  She  received  symptomatic  treat-
ment  and  anticoagulation  was  temporarily  suspended.  Minor
VCs  were  mainly  vascular  dissections  (59%)  and  pseudoa-
neurysms  (29%).  The  types  of  VCs  and  their  management
are  summarized  in  Table  3  and  Table  4.
Endovascular  treatment  was  used  in  13  of  22  patients
with  VCs  (59%)  and  was  successful  in  11  of  these  13  patients
(85%).  With  the  exception  of  one  arterial  dissection  treated
by  balloon  angioplasty  alone,  the  remaining  12  cases  ben-
eﬁted  from  stent  implantations  for  ipsilateral  ﬂow-limiting
arterial  dissections  (n  =  11)  or  pseudoaneurysm  (n  =  1).  The
ﬁrst  failed  case  occurred  in  a  major  VC  early  in  our  experi-
ence  (patient  27).  The  patient  developed  massive  bleeding
shortly  after  the  procedure  while  she  was  in  the  intensive
care  unit;  there  was  a  delay  in  diagnosis  in  the  context
of  obesity  (body  mass  index  >  30  kg/m2).  The  patient  was
taken  back  to  the  catheterization  laboratory  and  two  self-
expandable  covered  stents  for  a  common  femoral  artery
perforation  were  implanted.  Bleeding  persisted  and  the
patient  died,  despite  surgical  revision  in  the  operating  room.
Prostar  XL  10  failure  1  (1.0)
Aortoventricular  junction  rupture  1  (1.0)
Mesenteric  ischaemia  due  to  embolism  1  (1.0)
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Table  4  Vascular  complication  details  and  management.
Patient
number
Type  of  VC  Severity
according
to  VARC-2
Treatment  strategy  Stent  Treatment
success  at
30  days
1  Occlusive  dissection
involving  the  left  CFA
to  the  SFA  ostium
Minor  Implantation  of  two
stents
Uncovered
self-expandable  nitinol
stents
Yes
2  Right  inguinal
haematoma  with
transitory  crural  nerve
paresia
Major  Therapeutic
anticoagulation
stopped  and  transfusion
of  2  units  of  PRBCs
— Yes
3  Left  CFA
pseudoaneurysm
Minor  Thrombin  injection  —  Yes
6  Right  EIA  non-occlusive
dissection
Minor  Implantation  of  one
stent
Uncovered
self-expandable  nitinol
stent
Yes
8  Non-occlusive
dissection  involving  the
right  EIA  to  the  CFA
Minor  Implantation  of  one
stent
Uncovered
self-expandable  nitinol
stent
Yes
10  Right  CFA
pseudoaneurysm
Minor  Prolonged  manual
compression
— Yes
20  Left  inguinal
haematoma  requiring
duplex  ultrasonography
Minor  1  unit  of  PRBCs  —  Yes
23  Right  inguinal
haematoma  requiring
duplex  ultrasonography
Minor  Nihil  —  Yes
27  Percutaneous  vascular
device  closure  failure
on  right  CFA
Major  Implantation  of  two
stents
Covered  (polyethylene
terephthalate)
self-expandable  stents
No,  death
of patient
despite
emergent
surgical
rescue
29  Left  CFA
pseudoaneurysm
Minor  Surgical  intervention  —  Yes
31  Left  CFA  non-occlusive
dissection
Minor  Implantation  of  one
stent
Uncovered
self-expandable  nitinol
stent
Yes
32  Aortoventricular
junction  rupture  with
cardiac  tamponade
Major  Pericardiocentensis  —  No,
procedural
death
44  Left  CFA  non-occlusive
dissection
Minor  Implantation  of  one
stent
Uncovered
self-expandable  nitinol
stent
Yes
49  Left  EIA  non-occlusive
dissection
Minor  Implantation  of  two
stents
Uncovered
self-expandable  nitinol
stents
Yes
50  Right  CFA  occlusive
dissection
Major  Implantation  of  two
stents
Uncovered
self-expandable  nitinol
stents
No,  acute
stent
thrombosis
requiring
an
additional
endovascu-
lar
intervention
53  Right  EIA-CFA  junction
pseudoaneurysm
Minor  Implantation  of  one
stent
Covered  (polytetraﬂuo-
roethylene)
self-expandable  stent
Yes
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Table  4  (Continued)
Patient
number
Type  of  VC  Severity
according
to  VARC-2
Treatment  strategy  Stent  Treatment
success  at
30  days
55  Right  CFA  non-occlusive
dissection
Minor  Implantation  of  one
stent
Uncovered
self-expandable  nitinol
stent
Yes
95  Left  CFA  non-occlusive
dissection
Minor  Balloon  angioplasty  —  Yes
107  Mesenteric  ischaemia
following  valve
recapture
Major  Nihil  —  No,  death
at 7  days
108  Right  CFA  occlusive
dissection
Minor  Implantation  of  one
stent
Uncovered
self-expandable  nitinol
stent
Yes
110  Left  CFA
pseudoaneurysm
Minor  Duplex
ultrasound-guided
compression
—  Yes
111  Left  CFA  non-occlusive
dissection
Minor  Implantation  of  one
stent
Uncovered
self-expandable  nitinol
stent
Yes
CFA: common femoral artery; EIA: external iliac artery; PRBCs: packed red blood cells; SFA: superﬁcial femoral artery; VARC: Valve
Academic Research Consortium; VC: vascular complication.
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rIn  the  second  case  (patient  50),  the  patient  had  a  major
VC  with  one  external  iliac  and  one  common  femoral  non-
covered  stent  placed  for  an  acute  vessel  occlusion  occurring
at  the  end  of  the  TAVI  procedure,  and  required  subse-
quent  percutaneous  intervention  for  acute  iliofemoral  stent
thrombosis,  possibly  caused  by  vigorous  compression  at  the
time  of  bleeding  shortly  post-VC  procedure.  Among  the
seven  remaining  cases  of  VCs,  four  pseudoaneurysms  were
treated  by  surgery  (n  =  1),  thrombin  injection  (n  =  1)  or  man-
ual  or  ultrasound-guided  compression  (n  =  2),  while  the  three
cases  of  inguinal  haematoma  received  symptomatic  treat-
ment.  The  only  case  requiring  primary  surgery  was  operated
on  2  weeks  post-TAVI  because  of  a  common  femoral  artery
pseudoaneurysm  close  to  the  femoral  artery  bifurcation  and
resistant  to  external  compression.  At  30-day  and  6-month
follow-up,  all  surviving  patients  who  had  experienced  a  VC
were  asymptomatic;  none  had  required  further  reinterven-
tion  and  only  one  patient  with  a  VC  died  from  respiratory
failure  of  unknown  origin,  between  the  30-day  and  6-month
follow-up.  No  new  VC  occurred  between  the  30-day  and  6-
month  follow-up  when  considering  all  the  patients  included
in  this  series.
Procedural characteristics and outcomes
Procedural  characteristics  are  reported  in  Table  5.  Patients
with  VCs  had  a  signiﬁcantly  higher  quantity  of  con-
trast  media  injected  than  patients  without  VCs  (235.5
[135.5—335.5]  mL  vs  200.0  [125.0—275.0]  mL;  P  =  0.02),  but
there  were  no  differences  in  terms  of  ﬂuoroscopy  time  or
valve  size  used.  The  calcium  score  was  similar  in  patients
with  and  without  VCs  (P  =  0.53).  All  femoral  arteries  were
punctured  between  the  inferior  epigastric  artery  and  the
femoral  bifurcation.
D
I
TAll-cause  mortality  at  30  days  was  6%  (n  =  6).  Three  of
he  deaths  occurred  among  the  ﬁve  patients  with  major  VCs
patients  27,  32  and  107).  Mortality  at  30  days  was  signif-
cantly  higher  in  patients  with  major  VCs  than  in  patients
ithout  major  VCs  (60%  vs  3%;  P  =  0.001),  while  minor  VCs  did
ot  increase  30-day  all-cause  mortality  (6%  vs  6%;  P  =  1.0).
atients  with  VCs  had  a  higher  incidence  of  life-threatening
r  major  bleeding  than  patients  without  VCs  (23%  vs  5%;
 =  0.02),  but  no  difference  was  reported  in  terms  of  need
or  packed  red  blood  cell  transfusion.  Length  of  hospital  stay
as  similar  for  patients  with  VCs  (9  [2—16]  days)  and  without
Cs  (9  [3—15]  days).
All-cause  mortality  at  6  months  was  13%  (n  =  13),  four
eaths  (31%)  being  of  non-cardiovascular  origin.  All-cause
ortality  at  6  months  was  still  signiﬁcantly  higher  in  patients
ith  major  VCs  than  in  those  without  major  VCs  (80%  vs  9%;
 =  0.001),  while  minor  VCs  did  not  increase  the  6-month
ll-cause  mortality  rate  (6%  vs  14%;  P  =  0.7).
redictors of vascular complications
sing  logistic  regression  analysis,  no  independent  predictors
f  VCs  were  found  (Table  6).  However,  even  if  a  learning
urve  could  not  be  demonstrated  as  an  independent  predic-
or  of  VCs,  a  trend  toward  reduced  VC  rates  among  cases  in
he  second  half  of  the  cohort  should  be  acknowledged  (68%
f  VC  for  the  initial  half  versus  32%  for  the  second  half;  odds
atio  0.37,  95%  conﬁdence  interval  [CI]  0.13—1.03;  P  =  0.06).iscussion
n  our  single-centre  experience  with  fully  percutaneous  TF-
AVI  using  the  Medtronic  CoreValve  system,  VCs  following
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Table  5  Differences  in  procedural  and  30-day  outcomes  between  patients  with  and  without  vascular  complications.
Overall  Patients  with  VCs  Patients  without  VCs  P
(n  =  102) (n =  22)  (n  =  80)
Fluoroscopy  time
(minutes)
22.6  [9.9—35.3]  24.8  [7.1—42.5]  22.4  [10.9—33.9]  0.32
Amount  of  contrast  (mL) 215.0  [145.0—285.0] 235.5  [135.5—335.5] 200.0  [125.0—275.0]  0.02
General  anaesthesia 4  (3.9) 2  (9.1) 2  (2.5) 0.20
Valve  size  (mm)  0.33
23  2  (2.0)  1  (4.6)  1  (1.3)
26  58  (57.4)  15  (68.2)  43  (54.4)
29  38  (37.6)  6  (27.3)  32  (40.5)
31  3  (3.0)  0  3  (3.8)
Calcium  score  0.53
0  41  (40.6)  7  (31.8)  34  (43.0)
1  27  (26.7)  5  (22.7)  22  (27.9)
2  14  (13.9)  5  (22.7)  9  (11.4)
3  10  (9.9)  2  (9.1)  8  (10.1)
4  9  (8.9)  3  (13.6)  6  (7.6)
Distance  PSFB  (mm)  32.0  [15.4—48.6]  32.0  [14.4—49.6]  32.0  [15.7—48.3]  0.73
Distance  IEAPS  (mm) 27.5  [12.4—42.6]  26.6  [13.4—39.8]  27.6  [13.1—42.1]  0.48
Iliofemoral  vessel  minimal
diameter  (mm)
8.8 [6.9—10.8] 8.4  [7.0—9.8]  8.9  [7.0—10.8]  0.11
Bleeding
Life-threatening  5  (4.9) 3  (13.6) 2  (2.5) 0.07
Major  4  (3.9) 2  (9.1) 2  (2.5)  0.22
Life-threatening  or
major
9 (8.8) 5  (22.7) 4  (5.0) 0.02
Blood  transfusion  (number
of transfusions  of  ≥  2
units  of  PRBCs)
9 (8.8)  3  (13.6)  6  (7.5)  0.37
30-day  device  success  86  (84.3)  16  (72.7)  70  (87.5)  0.09
30-day  mortality
All  cause  6  (5.9)  4  (18.2)  2  (2.5)  0.02
Cardiovascular  5  (4.9)  4  (18.2)  1  (1.3)  0.01
New  permanent
pacemaker  implantation
20  (19.6)  5  (22.7)  15  (18.8)  0.7
Length  of  hospital  stay
(days)
9 [2—16]  9  [2—16]  9  [3—15]  0.57
Data are expressed as number (%) or median [interquartile range]. IEAPS: distance measured from the inferior epigastric artery to
puncture site; PRBCs: packed red blood cells; PSFB: distance measured from puncture site to femoral bifurcation; VC: vascular
complication.
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tAVI  are  the  most  frequent  adverse  events  (22%),  even
efore  the  need  for  permanent  pacemaker  implantation
20%).  According  to  the  VARC-2  criteria,  minor  VCs  were
ound  in  17%  of  the  cohort  and  major  VCs  were  found  in
%.  Several  other  studies  using  VARC  or  VARC-2  criteria
ave  reported  major  VC  rates  varying  from  4.3%  to  20.5%
4,8—16].
The  initial  VARC  criteria  were  revisited  in  2012  to  make
hem  more  suited  to  the  needs  of  clinical  trials.  When  focus-
ng  on  VCs,  the  major  changes  in  VARC-2  were  to  classify
Cs  treated  by  unplanned  endovascular  stenting  or  surgi-
al  repair  as  minor  VCs  —– instead  of  major  VCs  —– if  the
ascular  injury  did  not  lead  to  death,  life-threatening  or
ajor  bleeding,  visceral  ischaemia  or  neurological  impair-
ent.  As  a  direct  consequence,  we  would  expect  a  reduction
V
cn  major  VC  rates  in  most  studies.  In  our  experience,  major
Cs  according  to  VARC  occurred  in  18%  of  the  cohort  instead
f  5%  when  using  VARC-2,  and  the  association  between  VARC
ajor  VCs  and  mortality  at  30  days  was  already  present,  but
eaker  (22%  for  patients  with  VARC  major  VCs  versus  2%  for
atients  without  VARC  major  VCs;  P  =  0.008).  Indeed,  only
ne  patient  of  the  13  who  were  reclassiﬁed  as  having  VARC-
 minor  VCs  rather  than  VARC  major  VCs  died  at  26  days  from
 non-vascular,  non-valve-related  cause.  Furthermore,  when
onsidering  only  the  13  patients  with  VARC  major  VCs  who
ere  reclassiﬁed  as  having  VARC-2  minor  VCs,  30-day  mor-
ality  was  not  signiﬁcantly  higher  than  in  patients  without
ARC  major  VCs  (8%  vs  6%;  P  =  0.6).
Reporting  major  and  minor  VCs  separately  is  of  criti-
al  importance,  as  only  major  VCs  were  associated  with
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Table  6  Predictors  of  vascular  complications.
Variables  Univariate  Multivariable
OR  95%  CI P OR  95%  CI  P
Sex
Female
Male
0.95  0.36—2.54  0.92  0.82  0.28—2.37  0.71
Age  (years)
< 80
≥  80
0.99  0.32—3.05  0.98
BMI  (kg/m2)
< 25
≥  25
1.84  0.70—4.87  0.22
Diabetes  mellitus  0.88  0.31—2.51  0.80
Peripheral  vascular  disease  1.28  0.41—4.00  0.68
GFR  (mL/min/1.73  m2)
<  60
≥  60
1.73  0.61—4.92  0.30
STS  score  (%)
<  8
≥  8
2.23  0.86—5.80  0.10
LVEF  (%)
<  60
≥  60
2.30  0.81—6.47 0.12
Calcium  score
0—2
3—4
1.37  0.43—4.32  0.60  1.12  0.32—3.94  0.86
Learning  effect  (initial  half
versus  second  half)
0.38 0.14—1.04  0.06  0.37  0.13—1.03  0.06
BMI: body mass index; CI: conﬁdence interval; GFR: glomerular ﬁltration rate; LVEF: left ventricular ejection fraction; OR: odds ratio;
STS: Society of Thoracic Surgeons.
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vhigher  mortality.  Indeed,  in  a  substudy  of  the  PARTNER  trial,
Généreux  et  al.  demonstrated  a  fourfold  increase  in  the  30-
day  mortality  among  patients  with  VARC  major  VCs  (hazard
ratio  4.87,  95%  CI  2.02—11.75;  P  <  0.0001)  [4].  Our  results  are
in  line  with  this  previous  report,  as  we  found  a  signiﬁcantly
higher  mortality  rate  in  patients  with  major  VCs.  Finally,
we  encourage  the  use  of  the  VARC-2  criteria,  which  allow  a
more  meaningful  distinction  to  be  made  between  major  and
minor  VCs,  and  a  stronger  association  between  major  VCs
and  mortality.
The  traditional  treatment  for  VCs  following  TAVI  was  sur-
gical  reconstruction,  with  a  success  rate  approaching  100%.
However,  it  was  associated  with  an  incidence  of  postop-
erative  morbidity  of  up  to  25%  [17].  With  proper  training,
interventionalists  may  be  able  to  treat  the  majority  of  VCs
percutaneously.  A  percutaneous  strategy  has  several  advan-
tages,  including  the  lack  of  general  anaesthesia,  more  rapid
mobilization  and  decreased  in-hospital  complications,  such
as  wound  infections  [18,19].  In  a  study  of  149  patients  with
a  VC  rate  of  18%,  Stortecky  et  al.  showed  a  similar  clinical
outcome  in  patients  undergoing  percutaneous  management
and  patients  without  VCs  [20].  In  our  experience,  up  to  85%
of  attempted  cases  were  successfully  treated  by  a  percu-
taneous  approach,  and  none  of  the  surviving  patients  was
symptomatic  at  30  days  and  6  months.  Despite  encourag-
ing  results,  stent  implantation  at  the  level  of  the  common
[
u
wemoral  and  distal  external  iliac  arteries  should,  however,
e  considered  as  a  bailout  procedure.  Indeed,  stents  at  the
nguinal  fold  undergo  important  external  compressive  forces
nd  may  be  prone  to  fracture.  However,  the  incidence  of
tent  fracture  among  femoral  and  popliteal  treated  lesions
eported  in  literature  varies  signiﬁcantly  from  2%  to  65%,
nd  most  patients  with  stent  fracture  remain  asymptomatic
21—23]. Indeed,  in  today’s  TAVI  population,  which  involves
rail  and  elderly  patients,  external  compression  may  be
 lesser  issue  than  in  younger  and  more  active  patients.
inally,  the  use  of  covered  stents  might  impair  femoral
ccess  for  future  percutaneous  interventions,  but,  again,
his  is  not  a major  concern  in  the  present  TAVI  population.
As  TAVI  procedures  are  increasingly  performed,  preven-
ion  of  VCs  has  become  an  important  matter  of  concern.  In
his  context,  important  femoral  calciﬁcation,  female  sex,
entre  experience  and  a sheath  to  femoral  artery  ratio  >  1.05
ave  been  identiﬁed  as  independent  predictors  of  VCs  by
ultivariable  logistic  regression  analysis  [4,11,24—27].  A
emoral  puncture  above  the  inferior  epigastric  artery  or
elow  the  femoral  bifurcation  has  also  been  associated  with
n  increased  risk  of  VCs  and  retroperitoneal  bleeding,  as
ascular  compression  at  these  levels  lacks  sufﬁcient  support
28—30]. In  the  present  study,  all  puncture  sites  were  metic-
lously  assessed  using  crossover  ﬂuoroscopy  and  all  patients
ere  therefore  punctured  between  the  inferior  epigastric
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rtery  and  the  femoral  bifurcation.  No  independent  predic-
ors  of  VCs  were  found  in  our  cohort  (Table  6).  However,
e  can  show  a  trend  towards  a  learning-curve  effect  on  the
ccurrence  of  VCs.  This  reduction  in  VC  rate  over  time  can
e  explained  by  increased  operator  experience,  but  also  by
mproved  screening  strategies  for  selecting  patients  with
avourable  anatomy  before  performing  TF-TAVI.  In  this  con-
ext,  preprocedural  imaging  plays  a  major  role  in  adequate
liofemoral  axis  assessment.  In  addition  to  conventional
ngiography,  routinely  performed  since  the  beginning  of
ur  experience,  iliofemoral  MSCT  has  recently  become  the
ew  standard,  as  it  allows  three-dimensional  evaluation  of
ascular  tortuosity  and  calciﬁcation.  Moreover,  assessing
liofemoral  vessel  diameter  on  angiography  alone  may
verestimate  vessel  diameter  [31].  Therefore,  MSCT  should
e  considered  as  a  key  element  in  patient  screening.  To
vercome  sheath  insertion  difﬁculties  in  patients  with
ild  stenosis  or  calciﬁcation  of  the  iliofemoral  vessels  or
ith  small  diameters,  the  use  of  a  balloon-expandable
heath  (SoloPath,  Onset  Medical,  a  subdivision  of  Terumo
edical  Corporation,  Irvine,  CA,  USA)  can  be  an  attractive
lternative  to  minimize  the  risk  of  VC  occurrence  [32]. In
ur  series,  we  used  this  new  technology  in  seven  patients  in
he  context  of  calciﬁcation  or  borderline  vessel  diameter,
nd  we  did  not  experience  any  VCs.
tudy limitations
he  current  study  has  several  limitations.  First,  it  reports
 single-centre  TAVI  experience  with  a  limited  number  of
atients  and  a  reduced  power  for  statistical  analysis.  Sec-
ndly,  the  current  data  analyses  are  retrospective,  although
erived  from  a  prospectively  collected  database.  Finally,  the
ccess  strategy  was  mostly  based  on  angiographic  assess-
ent  and  clinical  judgement,  as  iliofemoral  axis  assessment
ith  MSCT  was  only  performed  in  a  minority  of  patients
n  =  36).
onclusions
n  conclusion,  despite  signiﬁcant  efforts  devoted  to  improv-
ng  clinical  outcomes,  VCs  following  fully  percutaneous
F-TAVI  remain  frequent.  Major  but  not  minor  VCs  are  asso-
iated  with  increased  mortality.  Percutaneous  management
f  VCs  is  feasible  and  safe,  and  surgery  is  rarely  needed.
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